Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma

BACKGROUND: The overall prognosis of glioblastoma (GBM) remains dismal, particularly for patients with unmethylated O6-methylguanine-DNA-methyltransferase (MGMT) promoter. In this phase II trial, we tested the combination of the antiangiogenic agent sunitinib with radiotherapy and temozolomide (TMZ)...

Descripción completa

Detalles Bibliográficos
Autores principales: Faye, Mame Daro, Easaw, Jacob, De Robles, Paula, Agnihotram, Raman, Torres-Vasquez, Alexander, Lamonde, Frederic, Petrecca, Kevin, Owen, Scott, Panet-Raymond, Valerie, Shenouda, George, Souhami, Luis, Azam, Maryam, Hossain, Bushra, Alkass, Jad, Sabri, Siham, Abdulkarim, Bassam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530294/
https://www.ncbi.nlm.nih.gov/pubmed/37771465
http://dx.doi.org/10.1093/noajnl/vdad106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530294/
https://www.ncbi.nlm.nih.gov/pubmed/37771465
http://dx.doi.org/10.1093/noajnl/vdad106

Ejemplares similares